The calculated difference of PD-L1 expression levels in the tumor core and invasive zone was more than 1% in 51 patients (34.9%), more than 10% in 37 patients (25.3%), more than 25% in 13 patients (8.9%) and more than 50% in 15 patients (10.3%). Here, CD274 is linked to neoplasm.